School Committee learns more about GLP-1 insurance coverage decision
GLP-1, short for glucagon-like peptide-1, is a type of medication based on the hormone of the same name that helps regulate blood sugar and appetite by stimulating insulin release and slowing stomach emptying. Originally designed as weight loss drugs due to their ability to decrease appetite, the drugs have become effective tools for individuals battling diabetes as well.
During the
According to DeLacey, the cost of GLP-1 rose tenfold from Fiscal Year 2023 to 2025 and rose five times between Fiscal Year 2024 and 2025. DeLacey added that several health insurance carriers had lost hundreds of millions of dollars due in large part to the drug cost spike and that several nearby local government entities had stopped covering GLP-1 medications for cost reasons as well.
DeLacey went on to share a recent study showed that if these drugs were covered by Medicare, the annual national cost would be approximately
"It's just so cost prohibitive, for the return you get, it doesn't make a lot of sense," he said.
If the district were to offer these drugs, DeLacey estimated that it would cost the district an additional
DeLacey and Upton told the board that employees were not told that they couldn't obtain the drugs, only that they would no longer be covered under the district's health insurance. Employees could still obtain reimbursement for costs of the pills through health savings accounts, direct sales from manufacturers or other alternatives. It was noted there would be reviews of the drugs' costs in the future to see if they would become more affordable. Ward 2
Members of the board expressed frustration that they were unable to do more to help the staff members that came forward earlier in the month and appreciated that those staff members brought the issue to their attention.
Ward 4
Ward 5
"This was not a decision that was lightly made, it is incredibly difficult to make a cut like this," said O'Connell. "But when we're in a situation where the district does not necessarily have the budget that it needs and was requested, we have to make these kinds of decisions."



Gallego supports bill capping prices for medications
September 2025 Monthly
Advisor News
- CFP Board appoints K. Dane Snowden as CEO
- TIAA unveils ‘policy roadmap’ to boost retirement readiness
- 2026 may bring higher volatility, slower GDP growth, experts say
- Why affluent clients underuse advisor services and how to close the gap
- America’s ‘confidence recession’ in retirement
More Advisor NewsAnnuity News
- Insurer Offers First Fixed Indexed Annuity with Bitcoin
- Assured Guaranty Enters Annuity Reinsurance Market
- Ameritas: FINRA settlement precludes new lawsuit over annuity sales
- Guaranty Income Life Marks 100th Anniversary
- Delaware Life Insurance Company Launches Industry’s First Fixed Indexed Annuity with Bitcoin Exposure
More Annuity NewsHealth/Employee Benefits News
- Reports Outline Insurance Study Results from RAND Corporation (The Unaffordability of Affordable Care Act Health Insurance Plans): Insurance
- Recent Reports from National Yang Ming Chiao Tung University Highlight Findings in Women’s Health (Health-care utilization after domestic violence: A nationwide study in Taiwan comparing individuals with and without intellectual disability): Women’s Health
- WHAT THEY ARE SAYING: LOWERING PREMIUMS MEANS ADDRESSING THE TRUE DRIVERS OF HIGHER HEALTH CARE COSTS
- Health insurance increase of $1,100 (or around $4,000 for a family of 4) creates big questions
- Researchers at U.S. International University Publish New Data on Health Insurance (The Combined Effects of Digital Health Interventions on Universal Health Coverage Equity in Kenya: An Integrated Approach): Health Insurance
More Health/Employee Benefits NewsLife Insurance News